Billions At Stake As Generic Approvals Open Up Japan Big Sellers
Executive Summary
Japan has approved a new batch of first-time and other generic drugs that will be reimbursed and launched in June, putting at risk several billion dollars’ worth of combined sales of some major branded products.
You may also be interested in...
Jardiance Is The Star Of Boehringer’s Show, But Micardis Drag Spoils The Party
Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.
Sandoz Eyes Doubling Of Japan Business Despite Price Pressures
Sandoz is bullish on the prospects for its Japanese business, helped by an operating environment it sees as favoring generics and biosimilars and despite growing cost control pressures.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.